rubitecan

Also known as 9-nitrocamptothecin, Camptogen, 9NC, RF-2000

Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).

Research

164 papers

Rubitecan.Expert opinion on investigational drugs · 2006
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.The oncologist · 2005
Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).International journal of oncology · 2002
Alternative administration of camptothecin analogues.Expert opinion on drug delivery · 2005
Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts.Anti-cancer drugs · 2002

via PubMed

Wikidata facts

Mass: 393.0960852

Show 3 more facts

chemical formula: C₂₀H₁₅N₃O₆
canonical SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O
isomeric SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O

Sources (2)

via Wikidata · CC0

~2 min read

Article

4 sections

Contents

History
Synthesis
Use as anticancer drug
References

Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).

==History== On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA, and was accepted for filing in March 2004.